Zein Ahmad Fariz Malvi Zamzam, Sulistiyana Catur Setiya, Raffaelo Wilson Matthew, Pranata Raymond
Department of Internal Medicine, Faculty of Medicine, Universitas Swadaya Gunung Jati, Cirebon, Indonesia.
Department of Internal Medicine, Waled General Hospital, Cirebon, Indonesia.
J Intensive Care Soc. 2023 Aug;24(3):299-308. doi: 10.1177/17511437221121234. Epub 2022 Aug 26.
This study aims to assess the association between mean platelet volume (MPV) and poor outcome in patients with COVID-19.
We performed a comprehensive literature search using the PubMed, Embase and Scopus databases with keywords "2019-nCoV" OR "SARS-CoV-2" OR "COVID-19" AND "mean platelet volume" OR "MPV" on 8 July 2021. The primary outcome was composite poor outcome, defined as severe COVID-19 or mortality. The pooled effect estimate was reported as mean differences in terms of MPV between the group with and without outcome.
There were 17 studies which consist of 4549 patients with COVID-19 were included in this study. The incidence of poor outcome was 25% (20%-30%). Mean MPV was found to be higher in the poor outcome group in compare to no poor outcome group (10.3 ± 1.9 fL vs 9.9 ± 1.7 fL). The mean MPV difference between both group was 0.47 fL [95% CI 0.27, 0.67], < 0.001; : 62.91%, < 0.001). In the sub-group analysis, patients with severe COVID-19 had higher MPV (mean difference 0.54 fL [95% CI 0.28, 0.80], < 0.001; : 54.84%, = 0.014). Furthermore, MPV was also higher in the mortality group (mean difference 0.54 fL [95% CI 0.29, 0.80], = 0.020; : 71.11%, = 0.004). Meta-regression analysis showed that the association between MPV and poor outcome was not affected by age ( = 0.789), gender ( = 0.167), platelets ( = 0.056), white blood cells ( = 0.639), and lymphocytes ( = 0.733).
This meta-analysis indicated that increased MPV was associated with severity and mortality in patients with COVID-19. Further research is needed to determine the optimum cut-off point.
本研究旨在评估新型冠状病毒肺炎（COVID-19）患者平均血小板体积（MPV）与不良预后之间的关联。
2021年7月8日，我们使用PubMed、Embase和Scopus数据库进行了全面的文献检索，关键词为“2019 - 新型冠状病毒”或“严重急性呼吸综合征冠状病毒2”或“COVID - 19”以及“平均血小板体积”或“MPV”。主要结局为复合不良结局，定义为重症COVID - 19或死亡。汇总效应估计值以有结局组和无结局组之间MPV的均值差异表示。
本研究纳入了17项研究，共4549例COVID - 19患者。不良结局的发生率为25%（20% - 30%）。发现不良结局组的平均MPV高于无不良结局组（10.3±1.9飞升对9.9±1.7飞升）。两组之间的平均MPV差异为0.47飞升[95%置信区间0.27，0.67]，P<0.001；I²：62.91%，P<0.001）。在亚组分析中，重症COVID - 19患者的MPV较高（平均差异0.54飞升[95%置信区间0.28，0.80]，P<0.001；I²：54.84%，P = 0.014）。此外，死亡组的MPV也较高（平均差异0.
